Mineralocorticoid Receptor Antagonists in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT02809963
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 140 participants
- Sponsor
- Registry
-
NCT02809963
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT02809963. Randomized; double masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Mineralocorticoid Receptor Antagonists in Type 2 Diabetes
- Condition
- Diabetes Type 2
- Intervention (Drug)
- Eplerenone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Herlev Hospital
Record details
- Record id
cardio:ct-nct02809963- Content hash
3bdb1c7246a601468913d95d21e969c8577ccba07d9883451c1580ab4bcb4b70